🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT05424354
Recruiting Phase 4

Acute Partial Thickness Burn Study Comparing Transforming Powder Dressing to Standard of Care Dressing

NCT05424354 · tracked via the Priya Life Science USA tracker
Sponsor
ULURU Inc.
Phase
Phase 4
Started
2022-05-26
Last updated
2025-11-19

Condition(s) studied

Wounds and Injuries

Investigational drug(s) / intervention(s)

Altrazeal (R) Transforming Powder DressingStandard of Care burn dressing

Altrazeal (R) Transforming Powder Dressing: After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with Altrazeal TPD.

Standard of Care burn dressing: After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with the institution's standard of care burn dressing.

Study summary

This study is being performed to assess the effectiveness of Altrazeal(R) Transforming Powder Dressing (TPD) in patients with partial thickness burns compared to the current standard of care (SOC) dressing. Adult men and women 18-65 years old who are hospitalized with an acute (meaning the burn injury occurred less than 72 hours prior to enrollment in the study) partial thickness burn wound, less than 20 percent of total body surface area may be considered. Subjects will be randomized in a 1:1 ratio to either SOC or TPD. Subjects will be followed for up to 28 days after enrollment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Hospitalized patients who are receiving burn care; patients may be discharged when clinically stable and continue with outpatient treatment. * Men and women (women cannot be pregnant or breast feeding) ages 18-65 years old * Wounds must be partial thickness, involving up to 20% of the total body surface area. * Burn injury should be less than 72 hours old * Willing and able to comply with protocol mandated scheduled study visits/clinical evaluations. * Willing and able to provide written informed consent. Exclusion Criteria: * Known allergy to TPD or its components * Women who are pregnant, breast feeding, or plan to get pregnant during the study period. * Infected wounds * Presence of any full thickness (third degree) burns * Electrical burns * Heavily draining burns due to underlying chronic lymphedema or other conditions * Concurrent clinical condition within the judgement of the clinician, pose a health risk to the patient, delay wound healing, or otherwise influence the outcome of the study. * History of poor wound healing and/or skin/immune system condition * Deemed by clinician not to be suitable * Unwilling or not able to provide consent or comply with protocol or required visits * Developmental disability/significant psychological disorder which can impair the subjects ability to provide informed consent, or participate in the study protocol * Active alcohol or substance abuse

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
University of California-Irvine Orange California Recruiting
MedStar Washington Hospital Center Washington D.C. District of Columbia Recruiting
Jackson Memorial Hospital UM/JMH Burn Center Miami Florida Recruiting
University of Louisville Health Louisville Kentucky Recruiting
Westchester Medical Center Valhalla New York Recruiting
University of Texas SW (Parkland) Dallas Texas Recruiting

More ULURU Inc. trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05424354 on ClinicalTrials.gov ↗ ← All trials in the USA